Contribution of Dolutegravir to Obesity and Cardiovascular Disease

Inclusion Criteria: Subjects must meet the following criteria to be eligible for participation in this study: * Age greater than or equal to 18 years with HIV-1 who have been virologically suppressed (HIV-1 RNA \< 50 copies for greater than or equal to 3 months on a non-integrase strand transfer inhibitor-based regimen * Have the ability to understand and sign an informed consent written in the English language Exclusion Criteria: Subjects meeting any of the following exclusion criteria are not to be enrolled in this study: * Age less than 18 years without HIV-1 infection * Has hypersensitivity or other contraindication to any of the components of the study * Has active diagnosis of untreated hepatitis due to any cause * Has a history or current evidence of any condition, laboratory abnormality or other circumstance ( including drug or alcohol use or dependence) that might confound the results of the study or interfere with the subject's participation for the full duration of the study * Is taking or is anticipated to require long term systemic immunosuppressive therapy, immune modulators, or any prohibited therapies from 60 days prior to Screening/Day 1 visit through to the end of study * Has documented or suspected dolutegravir-associated resistance mutations specifically: Q148H/K/R/N in combination with E138K or G1402/A or N155H. * Has a life expectancy less than or equal to one year * Is pregnant, breastfeeding, or expecting to donate eggs or sperm or conceive or f…